The global market consist of players such as AbbVie, Allergan plc, Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Novartis AG, Pharmaxis Ltd, PTC Therapeutics, and Vertex Pharmaceuticals Incorporated are some of the prominent players at the forefront of competition in the global cystic fibrosis market and are profiled in MRFR Analysis report.
Global Cystic Fibrosis Market - Overview:
According to a recent study report published by the
Market Research Future analysts, the global cystic fibrosis
therapeutics market is growing at a double digit CAGR. The
major growth in the cystic fibrosis market was observed with the introduction
of Kalydeco drug by Vertex pharmaceutical in 2012. There has been constant
development of new drugs and therapies for treating cystic fibrosis. Cystic
fibrosis foundation (CFF) has always been in support of the companies involved in
the research and development of the cystic fibrosis drugs. The financial
support from CFF is influential in the growth of the cystic fibrosis market
worldwide.
That being said, there are few hurdles as well in
growth of this market. Currently there are approximately 1900 identified CFTR
mutations that are responsible for the development of the disease condition.
Many are yet to be identified. At present, treatments are available for nearly
half the mutations. CF being the rare disease, and due to the limited
information available, the extensive research is required. The research and
development cost for the cystic fibrosis is very high leading to the massive
prices of the end products. High cost of the drugs and treatments is one of the
factors that hinder the growth of the cystic fibrosis market.
Global Cystic Fibrosis Market - Competitive Analysis:
The global market for cystic fibrosis is dominated by
American pharmaceutical company Vertex Pharmaceuticals Incorporated. With
two FDA approved CFTR modulator drugs Kalydeco & Orkambi, Vertex
Pharmaceuticals secured a top spot with the market share of 46% in the global
cystic fibrosis market. Kalydeco and Orkambi are the drugs that affect the
disease at a genetic level where as all the other drugs from different
companies deal with the disease symptoms and associated problems. Currently
there is no competition for the Kalydeco and Orkambi. Moreover the Vertex is on
the verge of developing their next and better drug “triple combo” which is
expected to cover 90% of the total identified CFTR mutations. This development
is the strong reason for Vertex pharmaceutical to be on top of the table in the
near future as well.
Apart from the Vertex, there are some companies which
are manufacturing different drugs for the treatment for the cystic fibrosis.
These companies have drug products such as Roche- Pulmozyme, Abbvie- Creon,
Gilead- Cayston, Novartis- TOBI Podhaler, Allergan- Zenpep, Chiesi- Pertzye,
and few others. As these products help patients in managing the cystic fibrosis
symptoms and are consumed daily, these companies have fair amount of share in
the market. Additionally, there are other companies which such as Pharmaxis,
PTC therapeutics, Janssen Pharmaceuticals, Inc which are involved in the
development of the treatments for the symptoms of cystic fibrosis.
Global Cystic Fibrosis Market - Regional
Analysis;
Cystic fibrosis can occur in both genders as well as
in all ethnic groups and races. However the incidences of cystic fibrosis
varies across the globe. Cystic fibrosis is more common among the Caucasians.
Hence the disease is more prevalent in North America, Europe, and Australia.
However cystic fibrosis can also affect Latinos, American Indians, African, and
Middle Eastern population.
North America is one of the majorly affected region
by the deadly disease cystic fibrosis. The United States is among the countries
with highest incidence rates of cystic fibrosis. According to cystic fibrosis
foundation, more than 30,000 patients are living with cystic fibrosis in the
United States. Nearly, 1000 new cystic fibrosis cases are diagnosed each year.
According to CFF’s national patient registry, the median age of the person with
cystic fibrosis is currently 33.4 years. The average life expectancy of the CF
patients has increased significantly as compared to the patients 30 years back.
European region is also largely affected by cystic
fibrosis. According to European Cystic Fibrosis Society (ECFS), considering the
26 major countries in Europe, more than 35,500 people were suffering from
cystic fibrosis in 2014. Among the CF patients in Europe, 51.8% were adults
with age 18 years or more and 48.2% were less than 18 years old. Countries like
United Kingdom, Ireland, Romania, and Bulgaria have the high birth prevalence of
CF.
The prevalence of cystic fibrosis is seen to be very
low in the Asian region. There is limited information available about CF in
Asia, it is likely that the disease is highly underdiagnosed in this region
including the Indian subcontinent. It is due to medical community’s lack of
knowledge about CF and poor access to the medical and healthcare facilities for
cystic fibrosis patients.
The incidence of cystic fibrosis in Middle East
varies according to the ethnic background. However, the CF prevalence in Middle
East is low as compared to the North American and European region. There are no
accurate CF prevalence number for the Northern African countries, but it is
expected to be low due to the racial factor and no European genetic mixture.
Access Complete
Report @ https://www.marketresearchfuture.com/reports/cystic-fibrosis-market-1825
2022
Available At Market Research Future
About
Market Research Future:
At Market Research Future (MRFR), we enable
our customers to unravel the complexity of various industries through our
Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
MRFR team have supreme objective to provide
the optimum quality market research and intelligence services to our clients.
Our market research studies by Components, Application, Logistics and market
players for global, regional, and country level market segments, enable our
clients to see more, know more, and do more, which help to answer all their
most important questions.
In order to stay updated with technology
and work process of the industry, MRFR often plans & conducts meet with the
industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com
NOTE
: Our team of researchers are studying Covid19 and its impact on various
industry verticals and wherever required we will be considering covid19
footprints for a better analysis of markets and industries. Cordially get in
touch for more details.
